Pharmacokinetics and Buccal Mucosal Concentrations of a 15 Milligram per Kilogram of Body Weight Total Dose of Liposomal Amphotericin B Administered as a Single Dose (15 mg/kg), Weekly Dose (7.5 mg/kg), or Daily Dose (1 mg/kg) in Peripheral Stem Cell Transplant Patients

被引:27
作者
Gubbins, Paul O. [1 ]
Amsden, Jarrett R. [2 ]
McConnell, Scott A.
Anaissie, Elias J. [3 ]
机构
[1] Univ Arkansas Med Sci, Coll Pharm, Dept Pharm Practice, Little Rock, AR 72205 USA
[2] Butler Univ, Coll Pharm, Indianapolis, IN 46208 USA
[3] Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
关键词
ANTIFUNGAL PHARMACODYNAMIC CHARACTERISTICS; INVASIVE PULMONARY ASPERGILLOSIS; MURINE SYSTEMIC CANDIDIASIS; TISSUE CONCENTRATIONS; LIPID FORMULATIONS; MASS-BALANCE; CLINICAL USE; AMBISOME; EFFICACY; MODEL;
D O I
10.1128/AAC.01448-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The pharmacokinetics and safety of extended-interval dosing of prophylactic liposomal amphotericin B (L-AMB) in peripheral stem cell transplant recipients were evaluated. The patients received L-AMB daily at 1 mg/kg of body weight or weekly at 7.5 mg/kg or received L-AMB as a single dose (15 mg/kg). The buccal mucosal tissue concentrations of L-AMB were measured. Of the 24 patients enrolled, 5 withdrew after the initial dose due to an infusion-related reaction (n = 2) or significant increases in the serum creatinine (Scr) levels (n = 3). Weekly L-AMB dosing (7.5 mg/kg) produced mean plasma concentrations of > 0.300 mu g/ml for the first 7 days and > 0.220 mu g/ml for 7 days after the second dose. A single L-AMB dose (15 mg/kg) produced mean plasma concentrations of > 0.491 mu g/ml for at least 7 seven days. These concentrations are within the range of the MICs reported in the literature for susceptible strains of Candida and are at the lower limits of the MICs for Aspergillus spp. Extended-interval dosing produced buccal mucosal tissue concentrations well in excess of the MICs reported in the literature for susceptible strains of Candida and Aspergillus spp. Infusion-related reactions occurred in 24% of the patients. Baseline and end-of-study Scr, electrolyte (K+, Mg2+, PO4), and serum transaminase levels were similar across the dosage groups. Five (31%) patients met the nephrotoxicity definition prior to completion of the study. Patients in the weekly or single-dose groups experienced nephrotoxicity significantly faster than the patients in the daily dosing cohort. A weekly L-AMB dose (7.5 mg/kg) or a single L-AMB dose (15 mg/kg) produced sufficient concentrations in plasma and highly vascular tissue to warrant further studies of the safety, efficacy, and practicality of the weekly prophylactic administration of L-AMB.
引用
收藏
页码:3664 / 3674
页数:11
相关论文
共 33 条
[1]   Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis [J].
Adler-Moore, JP ;
Olson, JA ;
Proffitt, RT .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (06) :1096-1102
[2]   Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models [J].
Andes, D ;
Safdar, N ;
Marchillo, K ;
Conklin, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) :674-684
[3]   Clinical utility of antifungal pharmacokinetics and pharmacodynamics [J].
Andes, D .
CURRENT OPINION IN INFECTIOUS DISEASES, 2004, 17 (06) :533-540
[4]   Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model [J].
Andes, D ;
Stamsted, T ;
Conklin, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :922-926
[5]   Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate [J].
Bekersky, I ;
Fielding, RM ;
Dressler, DE ;
Lee, JW ;
Buell, DN ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :834-840
[6]   Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans [J].
Bekersky, I ;
Fielding, RM ;
Dressler, DE ;
Lee, JW ;
Buell, DN ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :828-833
[7]   Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers [J].
Bekersky, I ;
Fielding, RM ;
Dressler, DE ;
Kline, S ;
Buell, DN ;
Walsh, TJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (09) :963-971
[8]  
Boswell GW, 1998, ANTIMICROB AGENTS CH, V42, P263
[9]   Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice [J].
Chang, CW ;
Barber, L ;
Ouyang, C ;
Masin, D ;
Bally, MB ;
Madden, TD .
BRITISH JOURNAL OF CANCER, 1997, 75 (02) :169-177
[10]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095